期刊文献+

益气活血解毒方治疗肾癌作用机制的动物实验研究 被引量:6

Research on Yiqi Huoxue Jiedu Formula on Mice Renal Cell Carcinoma
原文传递
导出
摘要 目的:研究"益气活血解毒方"对肾癌移植瘤的作用机制。方法:①将体外培养的小鼠Renca肾癌细胞分为对照组、氟尿嘧啶组和益气活血解毒方组。分别加入RPMI 1640培养液、氟尿嘧啶(4 mg/mL)、益气活血解毒方(300μg/mL),48 h后,四甲基偶氮唑蓝(MTT)法测定细胞增殖。②将36只荷瘤小鼠随机分为生理盐水组、氟尿嘧啶组和益气活血解毒方组,每组12只,分别于移植瘤内多点注射生理盐水、氟尿嘧啶、益气活血解毒方治疗28 d。对抑瘤率、PTEN、Survivin、VEGF和P-gp在小鼠肾癌移植瘤中的表达进行分析。结果:①在体外实验中,益气活血解毒方能明显抑制肿瘤细胞增殖,抑制率为43.02%。②在体内实验中,益气活血解毒方组抑瘤率为29.48%,氟嘧啶组抑瘤率为2.84%。益气活血解毒方组Survivin、VEGF、P-gp和PTEN蛋白阳性表达率分别为:25.0%、41.7、41.7%、91.7%,氟嘧啶组四种蛋白分别阳性表达率为41.7%、58.3%、83.3%、58.3%,生理盐水组四种蛋白分别阳性表达率为100%、91.7%、75.0%、16.7%,差异有统计学意义。结论:益气活血解毒方在体内外均有较强的抑制肾癌的作用,其抗肿瘤作用机制是多靶点、多通道的。 Objective:To observe the effect of Yiqi Huoxue Jiedu Formula on mice renal carcinoma. Methods:(1)The cell line of Renca mice renal cell carcinoma was treated with Yiqi Huoxue Jiedu Formula,5 - FU and RPMI 1640 culture medium, respectively. MTT assay was used to evaluate the cytotoxic effects of Yiqi Huoxue Jiedu Formula on Renca cells. (2)The model of RCC was established in mice. Comparative analysis between control and experimental groups on the sur- vival of mice and the growth of tumor. Expressions of PTEN, Survivin, VEGF and P - gp were evaluated by the method of immunohistochemistry. Results:Yiqi Huoxue Jiedu Formula inhibited the growth of Renca ceils significantly in vivo. The average tumor weight was far lighter than that in control group. Yiqi Huoxue Jiedu Formula significantly increased the ex- pression of PTEN in tumor tissue. And Yiqi Huoxue Jiedu Formula significantly decreased the expressions of Survivin, VEGF and P-gp in tumor tissue. Conclusion:Yiqi Huoxue Jiedu Formola can induce the multiple anti -RCC effect.
出处 《中华中医药学刊》 CAS 2013年第4期804-807,I0002,共5页 Chinese Archives of Traditional Chinese Medicine
基金 山西省科技攻关计划资助项目(20090311066)
关键词 益气活血解毒方 肾癌 小鼠 Yiqi Huoxue Jiedu Formula renal cell carcinoma mice
  • 相关文献

参考文献11

  • 1魏恩.坎贝尔-沃尔什泌尿外科学[M].9版,北京:北京大学出版社,2009:1668-1669.
  • 2Liou LS, Shi T, Duan ZH, et al. Microarray gene expression profi- ling and analysis in renal cell carcinoma[ J]. BMC Uro1,2004 ,4 (1) :9.
  • 3Wood C, Srivastava P. An adjuvant autologous therapeutic vaccine (HSPPC -96, vitespen)versus observation alone for patients at high risk of recto'fence after nephrectomy for renal cell carcino- ma : a muhicentre, open - label, randomised phase IH trial [ J ]. Lancet ,2008,372 ( 9633 ) : 145 - 154.
  • 4AKIHIKO MA'ISUMOTO, KYOKO I4ARAGUCHI. Immunothera- py against metastatic renal cell carcinoma with mature dendritic cells [ J ]. International Journal of Urology,2007,14:277 - 283.
  • 5Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa- 2a for Treatment of metastatic renal cell carcino- ma : a randomised, double - blind phase 111 trial [ J ]. Lancet,2007, 370(9605 ) :2103 - 2111.
  • 6Grimm O, Perren A, Weng LP, et al. Diffrential nuclear and cyto- plasmec expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors [ J ]. Am J Pathol, 2000, 156 (5) : 1693 - 1700.
  • 7Atimov A, Li C, Gizatullin R, et al. Somatic mutation and homozy- gous deletion of PTEN/MMACI gene of 10q23 in renal cell car- cinoma [ J ]. Anticancer Res, 1.999,19 (50) :3841 - 3846.
  • 8齐小康,李响.血管内皮生长因子在肾癌中表达及其意义的研究进展[J].华西医学,2008,23(3):673-675. 被引量:2
  • 9Rioux - Leclercq N, Fergelot P, Zerrouki S, et al. Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases [ J ]. Hum Pathol, 2007,38 (10) :1489 - 1495,.
  • 10Shin S,Sung B J, Cho YS, et al. An anti - apoptotic protein hu- man survivin is a direct inhibitor of Caspase - 3 and - 7 [ J ]. Biochem,2001,40(4) : 1117 - 1123.

二级参考文献24

  • 1夏军,骆平,王晖,雷益,刘品霓,徐化剑,陈志刚.肾癌多层螺旋CT成像与肿瘤血管形成的相关性[J].南方医科大学学报,2006,26(5):629-631. 被引量:4
  • 2Klatte T, Bohm M, Nelius T, et al. E- valuation of peri - operative peripheral and renal venous levels of pro - and anti - angiogenic factors and their relevance in patients with renal cell carcinoma [ J ]. BJU Int, 2007, 100 (1): 209-214.
  • 3Baldewijns MM, Thijssen VL, Van den Eynden GG, et al. High - grade clear cell renal cell carcinoma has a higher angiogenic activity than lowgrade renal cell carcinoma based on histomorphological quantification and qRTPCR mRNA expression profile [J]. BrJ Cancer, 2007, 96 (12): 1888 - 1895.
  • 4MacLennan GT, Bostwick DG . Microvessel density in renal cell carcinoma: lack of prognostic significance [ J ]. Urology, 1995, 46 (1): 27-30.
  • 5Raica M, Cimpean AM, Anghel A, et al. Immtmohistochemical expression of vascular endothelial growth factor (VEGF) does not correlate with microves.sel density in renal cell carcinoma [ J]. Neoplasma, 2007, 54 (4) : 278 - 284.
  • 6Djordjevic G, Mozetic V, Mozetic DV, et al. Prognostic significance of vascular endothelial growth factor expression in clear cell renal cell carcinoma [J]. Pathol Res Pract, 2007, 203 (2): 99-106.
  • 7Yao X, Qian CN, Zhang ZF, et al. Two distinct types of blood vessels in clear cell renal cell carcinoma have contrasting prognostic implications [J]. Clin Cancer Res, 2007, 13 (1): 161-169.
  • 8Mertz K, Demichdis F, Kim R, et al. Automated imamnofluorescence analysis de- fines microvessel area as a prognostic parameter in clear cell renal cell cancer [J]. Hum Pathol, 2007, 38 (10): 1454-1462.
  • 9Rioux- Leclercq N, Fergelot P, Zerrouki S, et al. Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases [J]. Hum Pathol, 2007, 38 (10): 1489 - 1495.
  • 10Bensalah K, Rioux- Leclercq N, Vinceu- dean S, et al. Is tumour expression of VEGF associated with venous invasion and survival in pT3 renal cell carcinoma? [ J ] Prog Urol, 2007, 17 (2): 189- 193.

共引文献1

同被引文献68

  • 1万崇华,陈明清,张灿珍,汤学良,孟琼,张晓磬.癌症患者生命质量测定量表EORTC QLQ-C30中文版评介[J].实用肿瘤杂志,2005,20(4):353-355. 被引量:1481
  • 2韩子敏,王巧凤,高福音,任玉川,王玉涛,杨凯军,韩霜.黄芪与川芎嗪注射液加免疫化学治疗转移性肾癌的临床观察[J].中国中西医结合肾病杂志,2005,6(8):481-482. 被引量:9
  • 3林建华,张文明,朱维钦,杨滨.骨肿瘤、骨转移癌患者免疫功能变化及临床意义[J].中华骨科杂志,1996,16(8):495-497. 被引量:2
  • 4WeinAJ,郭应禄,周立群译.坎贝尔-沃尔什泌尿外科学[M].9版.北京:北京大学医学出版社,2009:2645-2648.
  • 5那彦群,叶章群,孙颖浩,等.中国泌尿外科疾病诊断治疗指南[M].北京:人民卫生出版社,2013:439.
  • 6Motzer R J, Aqarwal N, Beatd C, et al. NCCN clinical practice guidelines in oncology: kidney cancer[ J]. J Natl Compr Cane Netw, 2009,7(6) :618 -630.
  • 7Ljungberg B, Cowan NC, Hanbury DC, et al. Cuidelines on tenal cell carcinoma[ J]. European urology, 2010,58:398 -406.
  • 8Liou LS, Shi T, Duan ZH, et al. Microarray gene expression profi- ling and analysis in renal cell carcinoma[ J]. BMC Urol,2004,4 (1):9-20.
  • 9Subramanian VS, Stephenson A J, Goldfarb DA, et al. Utility of pre- operative renal artery embolization for management of renal tumors with inferior vena caval thrombi [ J ]. Urology,2009,74 ( 1 ) : 154 - 159.
  • 10Perez Valdivieso JR, Bes-Rastrollo M, Manedero P, et al. Karnofsky performance score in acute renal failure as a predictor of short-term survival[ J ]. Nephrology ,2007,12 (6) :533 - 538.

引证文献6

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部